Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer

Award Number: R01CA288880
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2029

Group Awards By:

View Award Description

Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer - PROJECT SUMMARY/ABSTRACT Current standard tri-modality therapy (chemotherapy, radiation, and surgery) for locally advanced rectal cancer is associated with high morbidity and only cures disease in about 75% of patients. We hypothesize that a biomarker-driven approach that gives matched targeted therapy to patients early in the treatment of locally advanced rectal cancers will lead to high anti-tumor activity and provide the chance to avoid radiation and/or surgery and its associated morbidities. We have already pioneered such an approach for mismatch repair deficient locally advanced rectal cancer, where clinical complete response was seen in all patients who completed 6 months of upfront treatment with immune checkpoint inhibitors (23/23, 100% complete clinical response), allowing for the omission of radiation and/or surgery. In this proposal, we focus on patients with HER2-amplified rectal cancer and hypothesize that induction therapy with HER2-targeted treatment will lead to tumor regression and modify the need for tri-modality therapy. We propose an investigator-initiated phase II study (NCT05672524; MSK IRB# 22-185) that recently opened to enrollment; all patients will receive tucatinib plus trastuzumab induction HER2-targeted therapy for 6 weeks and continue tucatinib plus trastuzumab with addition of standard-of-care chemotherapy for 4 months, followed by disease reassessment before standard chemoradiation and before surgery. Patients with clinical complete response to induction HER2 therapy alone or combined with chemotherapy, or to the combination followed by chemoradiation, will undergo observation with a chance for an organ-sparing management approach. Our central hypothesis is that the primary tumor will be highly sensitive to HER2-targeted therapy alone or in combination with standard chemotherapy, leading to a higher frequency of clinical complete response than with standard total neoadjuvant therapy. Treatment of rectal cancer in patients provides the unique opportunity to obtain on-treatment longitudinal tumor and blood samples to evaluate mechanisms of response and resistance. We hypothesize that levels of HER2 expression and consequent dependence on HER2 homodimers underlie drug response and will determine HER2 expression in biopsy samples and with 89Zr-trastuzumab PET/MRI and correlate with response rate and progression-free survival. Circulating tumor DNA will be tested as a biomarker for response. Established and newly generated patient-derived HER2-amplified colorectal cancer organoids will be used to model and study acquired resistance, taking advantage of our team's expertise in generating these three-dimensional, multi-cellular structures, which both recapitulate the biology of rectal cancer and provide a needed resource that expands the limited HER2- amplified rectal cancer models currently available. We hypothesize that key resistance mechanisms will consist of decreased HER2 expression, secondary alterations that activate ERK, and shifts in tumor transcriptional programs. Together, we will define the efficacy and biological effects of biomarker-directed therapy and aim to transform treatment for patients with HER2-amplified locally advanced rectal cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $402,600 )
2026	2026	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	000	3	3/9/2026	NON-COMPETING CONTINUATION	$402,600
														Subtotal = $402,600

Issue Date FY: 2025 ( Subtotal = $402,600 )
2025	2025	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	001	2	5/26/2025	NON-COMPETING CONTINUATION	$40,260
2025	2025	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	000	2	3/12/2025	NON-COMPETING CONTINUATION	$362,340
														Subtotal = $402,600

Issue Date FY: 2024 ( Subtotal = $402,600 )
2024	2024	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVENUE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	000	1	2/22/2024	NEW	$402,600
														Subtotal = $402,600

Grand Total All Awards = $1,207,800

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer

Award Number: R01CA288880

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer